ホーム › トリプルネガティブ乳がん › オハイオ
オハイオにおけるトリプルネガティブ乳がんの臨床試験
オハイオ内の拠点で、トリプルネガティブ乳がんに関する29件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05422794Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027), Cincinnati
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/25更新 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Cleveland Clinic - Mercy Hospital ( Site 0057), Canton
- Tri-County Hematology & Oncology Associates, Inc. ( Site 0076), Massillon
- Taylor Cancer Research Center ( Site 9500), Maumee
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06393374A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Cleveland Clinic, Cleveland
- Local Institution - 0102, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06618287First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Cleveland Clinic, Cleveland
- Ohio State University, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06657222Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care, Inc., Cincinnati
- Ohio State University CRS, Columbus
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05633654Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT03606967A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The Ohio State University (OSU) Wexner Medical Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06400472Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- University of Cincinnati Medical Center, Cincinnati
被験者募集中観察研究
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07211178A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Cleveland Clinic, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07029399A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Maumee
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- The Ohio State University, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/13更新 · NCT05985655SMP-3124LP in Adults With Advanced Solid Tumors
- Ohio State University, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/12更新 · NCT06526819Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05208762Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
- MetroHealth, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中
18歳以上 · 女性 · 2026/06/29更新 · NCT05677802A Study of LY4175408 in Participants With Advanced Cancer
- The Ohio State University (OSU) Wexner Medical Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT07046923I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Cleveland Clinic, Cleveland
- The Ohio State University, Stefanie Spielman Comprehensive Breast Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT01042379Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- The Christ Hospital Cancer Center, Cincinnati
- Ohio State University Medical Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/29更新 · NCT04468061Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中
40歳〜65歳 · 女性 · 2025/12/11更新 · NCT06582615A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- The Christ Hospital, Cincinnati
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/04更新 · NCT05902988Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Cleveland Clinic, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/10/29更新 · NCT06249048A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- The Ohio State University, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/09/09更新 · NCT06682793A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Gabrail Cancer Center Research, Canton
被験者募集中第2相
18歳以上 · 全性別 · 2025/06/19更新 · NCT06568692A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- Gabrail Cancer Center, Canton
被験者募集中第3相
18歳〜65歳 · 女性 · 2025/03/21更新 · NCT03671044ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。